Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Harvard BioscienceHBIO 53 Forward PE Ratio is 12.43 as of Sep. 06, 2026. GuruFocus rates HBIO with a GF Score™ of 53/100 and a GF Value™ of $12.30 (Possible Value Trap). The stock has 9 warning signs investors should review. Among 403 Medical Devices & Instruments companies, Harvard Bioscience ranks better than 75.19% on this metric.
Harvard Bioscience (NAS:HBIO) Forward PE Ratio Explanation
The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.
Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .
Harvard Bioscience Forward PE Ratio Related Terms
Harvard Bioscience Forward PE Ratio Historical Data
* Premium members only.
The historical data trend for Harvard Bioscience's Forward PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Harvard Bioscience Forward PE Ratio Chart
Harvard Bioscience Annual Data
Trend
2015-12
2016-12
2017-12
2018-12
2019-12
2020-12
2021-12
2024-12
2025-12
Forward PE Ratio
18.25
16.05
18.87
11.43
14.27
14.79
19.57
15.84
7.39
Harvard Bioscience Quarterly Data
2015-12
2016-03
2016-06
2016-09
2016-12
2017-03
2017-06
2017-09
2017-12
2018-03
2018-06
2018-09
2018-12
2019-03
2019-06
2019-09
2019-12
2020-03
2020-06
2020-09
2020-12
2021-03
2021-06
2021-09
2021-12
2022-03
2024-12
2025-03
2025-06
2025-09
2025-12
2026-03
Forward PE Ratio
18.25
10.04
19.92
13.61
16.05
16.26
16.45
19.72
18.87
24.39
26.74
21.88
11.43
19.61
10.53
11.99
14.27
14.43
35.46
27.17
14.79
19.65
20.96
23.98
19.57
15.06
15.84
13.56
9.27
3.55
7.39
49.68
HBIO vs MLSS, FEMY, POCI: Forward PE Ratio Comparison
For the Medical Instruments & Supplies subindustry, Harvard Bioscience's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Harvard Bioscience Forward PE Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Harvard Bioscience's Forward PE Ratio distribution charts can be found below:
* The bar in red indicates where Harvard Bioscience's Forward PE Ratio falls into.
It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.
Harvard Bioscience (HBIO) has a Forward PE Ratio of 12.43 as of Sep. 06, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Harvard Bioscience and its competitors. According to the industry distribution chart, Harvard Bioscience ranks #100 out of 403 companies in the Medical Devices & Instruments industry, placing it in the top 24.8%.
Is Harvard Bioscience's Forward PE Ratio too high?
Harvard Bioscience's current Forward PE Ratio is 12.43. The Medical Devices & Instruments industry median Forward PE Ratio is 17.75. Harvard Bioscience's value of 12.43 is 30% below this industry median. Based on the distribution chart, Harvard Bioscience ranks #100 out of 403 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Harvard Bioscience has a GF Score™ of 53/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Harvard Bioscience's Forward PE Ratio compare to MLSS and FEMY?
According to the Medical Devices & Instruments industry distribution chart, Harvard Bioscience ranks #100 out of 403 companies for Forward PE Ratio. This places Harvard Bioscience in the top 25% of its industry — outperforming the majority of peers. The industry median Forward PE Ratio is 17.75. Harvard Bioscience's value of 12.43 is 30% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Medical Devices & Instruments company?
The median Forward PE Ratio among Medical Devices & Instruments companies is 17.75, based on 403 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Harvard Bioscience's current Forward PE Ratio of 12.43 is 30% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Harvard Bioscience and its competitors. For the Medical Devices & Instruments industry, the median Forward PE Ratio is 17.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Harvard Bioscience's current Forward PE Ratio is 12.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Harvard Bioscience stock overvalued right now?
Based on GuruFocus' analysis, Harvard Bioscience (HBIO) is currently considered Possible Value Trap. The stock's GF Value™ is $12.30, compared to a current price of $8.06 — trading 34.5% below its estimated fair value. The current Forward PE Ratio is 12.43 and 30% below the Medical Devices & Instruments industry median of 17.75. Harvard Bioscience's overall GF Score™ is 53/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For Harvard Bioscience (HBIO), the current Forward PE Ratio is 12.43 as of Sep. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Harvard Bioscience (HBIO) Overvalued in 2026?
Based on GuruFocus' analysis, Harvard Bioscience stock appears to be undervalued.
The current stock price of $8.06 is trading 34.5% below its estimated GF Value™ of $12.30.
GuruFocus considers Harvard Bioscience to be Possible Value Trap.
Key valuation signals for HBIO:
Forward PE Ratio: 12.43
GF Value™: $12.30 vs. price of $8.06 (34.5% below fair value)
Industry Position: 30% below the Medical Devices & Instruments median (#100 of 403)
No single metric tells the full story. See the HBIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, products, and services that enable advances in life science applications, including research, drug and therapy discovery, bioproduction, and preclinical testing. The company organizes its product line into two product families: Cellular and Molecular Technologies (CMT) and Preclinical. The CMT product family supports molecular, cellular, organ, and organoid research, as well as bioproduction and in vitro testing, while the Preclinical product family provides products for preclinical research and testing, including data collection and analysis for safety and regulatory compliance. Its geographical segments include the Americas, Europe, Middle East and Africa, and Asia.
53GF Score
Get the complete analysis for HBIO
Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HBIO has been successfully added to your 
